Trading Signals: HTBX Stock Price Prediction and Forecast (Mon. Dec. 28, 2015 - Mon. May. 2, 2022)(Heat Biologics, Inc.)
| HTBX latest price $7.5600 (1.89%) ($7.3500 - $7.8400) on Mon. Dec. 7, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 5.08% (three month average) | RSI | 56 | Latest Price | $7.5600(1.89%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | HTBX declines -0.8% a day on average for past five trading days. | Weekly Trend | HTBX advances 2.7% a week on average for past two weeks. | Market Behavior | Value stocks sell-off for large cap. Growth stock rally for small cap. | Correlated ETFs | Broad market will support HTBX advance at 0% a week (0% probability) ARKG(34%) XBI(34%) ARKK(33%) BLOK(32%) ACES(31%) | Factors Impacting HTBX price | HTBX will decline at least -2.54% in a week (0% probabilities). VIXM(-21%) VXX(-20%) UUP(-15%) XLU(-4%) XLP(-3%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.54% (StdDev 5.08%) | Hourly BBV | 0.4 () | Intraday Trend | 2.9% | | | |
|
Inflection Point | Yes | 5 Day Moving Average | $7.57(-0.13%) | 10 Day Moving Average | $7.51(0.67%) | 20 Day Moving Average | $7.38(2.44%) | To recent high | -23.4% | To recent low | 13.7% | Market Cap | $832m | | | | Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Morrisville, NC. |